Sihmosa (Sinmosa) obtained approval for an additional indication for the GnRH antagonist Iseulti for endometriosis in Taiwan, as part of market expansion in Taiwan. The impact on sales forecasts has already been incorporated into the consolidated earnings forecast for the fiscal year ending March 2027.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4547","jir_company_name":"Kissei Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-11-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4547-20261111-01.pdf","jir_short_summary":"Sihmosa (Sinmosa) obtained approval for an additional indication for the GnRH antagonist Iseulti for endometriosis in Taiwan, as part of market expansion in Taiwan. The impact on sales forecasts has already been incorporated into the consolidated earnings forecast for the fiscal year ending March 2027.","jir_summary":"### Impact on Performance and Background\nThis announcement concerns the approval in Taiwan of an additional indication for the GnRH antagonist \"Iseulti\" for endometriosis and reports on the status of development and marketing rights in Taiwan through Sinmosa. The additional indication application was submitted in December 2025, launch in Taiwan occurred in March 2026, and the impact has been reflected in the consolidated earnings forecast for the fiscal year ending March 2027. Future market rollout and the progress of clinical trials may affect future results.\n\n### Outlook and Impact on Shareholders\nThe expansion of indications in the Taiwan market is an important part of regional strategy; however, this release does not present specific sales forecasts or time-series financial metrics. Depending on future approvals, launch schedule, pricing, and progress of distribution partnerships, indirect effects on revenue and profit may be expected. Investors should note the statement that this has been incorporated into the full-year forecast for the fiscal year ending March 2027 and await additional disclosures.","jir_financial_highlights":"Unknown: Unknown (Unknown)","jir_category":"","jir_hashtags":"#KisseiPharmaceuticalNonProprietary #TaiwanMarketExpansion","jir_key_figures":"Unknown: Net Sales\nUnknown: Operating Income\nUnknown: Net Income Attributable to Owners of Parent","jir_meta_title":"Kissei Pharmaceutical Co., Ltd. \u2014 Iseulti Approved for Additional Endometriosis Indication in Taiwan | November 2026","jir_meta_description":"Kissei Pharmaceutical Co., Ltd. announced approval of an additional indication for the GnRH antagonist Iseulti for endometriosis in Taiwan. Launched in March 2026 and the impact has been incorporated into earnings forecasts. Monitor future market rollout and clinical development progress.","jir_og_title":"Kissei Pharmaceutical Co., Ltd. \u2014 Iseulti Receives New Indication Approval in Taiwan | November 2026","jir_og_description":"Announcement of approval of an additional indication for Iseulti for endometriosis in Taiwan. Launched in March 2026, with impacts already reflected in performance forecasts. Watch market expansion developments.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8930,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-149759","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n